astria therapeutics glp-1 receptor agonist weight management diabetes treatments Evolution of GLP‐1 Agonists for Treatment GLP-1 receptor agonists are transforming

Exploring the pathogenesis of IIH: an inflammatory perspective

Reich, N

In a 10-week clinical trial, a daily dose of 20 mg oral semaglutide achieved a steady-state plasma concentration of 30 nM, and when daily dose of oral semaglutide was increased to 40 mg, the semaglutide plasma concentration reached about 60 nM (102), which was over a thousand times higher than the EC50 of semaglutide for GLP-1R activation (95)

Significant fluctuations in blood sugar levels can damage blood vessels in the retina if not well-controlled, potentially leading to serious vision problems and even blindness if left untreated

BMJ (2017) 359:j4849